STOPINFECTIONS

STOPINFECTIONS is a research project funded by the competitive program RETOS-COLABORACION 2019 of the State Research Agency of the Spanish Ministry of Science and Innovation. The goal of the project is to execute activities to support taking Vaxdyn’s technology for vaccine development to file a permit to enter clinical phase for prevention of pneumonia resistant to antibiotics.

Execution of STOPINFECTIONS in 2020-2022 is made by a consortium led by Vaxdyn. The partners are the National Microbiology Center (CNM) of the Spanish Institutes of Health “Carlos III” in Madrid, the Barcelona-based international pharmaceutical manufacturer Laboratorios Reig Jofré, and Leitat Technological Center (Barcelona).

PREVIOUS PROGRAMS

ACINETOCLINIC (2016-2019) was a project funded by the competitive program RETOS-COLABORACION 2016 of the Spanish Ministry of Science and Innovation, co-financed with the ERDF Programme of the European Union.

The project finished with completion of preclinical research of AcinetoVax, the first universal vaccine against drug resistant Acinetobacter baumannii (VXD-001). The research performed allowed conversion of a single product into a technological platform to deliver multivalent vaccine candidates against Gram-negative bacteria. These results made possible to execute the business plan of Vaxdyn and attract private investors that today are making possible to deliver vaccines for tackling antibiotic-resistant infections.

Execution was made by a consortium led by Vaxdyn. The partners were the Andalusian Healthcare Service, the University of Seville, Barcelona-based international pharmaceutical manufacturer Laboratorios Reig Jofré, and Leitat Technological Center (Barcelona).

1-HEALTH-RESPIRA (2018-2019) was a project funded by the competitive program RETOS-COLABORACION 2017 of the Spanish Ministry of Science and Innovation, co-financed with the ERDF Programme of the European Union.

The project finished with experimental trials in porcine of vaccines to prevent respiratory viral and bacterial diseases in piglets that are currently treated with antibiotics, leading to the appearance and spread of antibiotic-resistant pathogens. Vaxdyn tested its technological platform for raising immunity in pigs for applications in the veterinary industry, leading a consortium formed by the following partners: the biotech group ADL Bionatur Solutions, who tested viral subunit vaccines; the Institute of Parasitology and Biomedicine “López Neyra” of the CSIC in Granada, who carried mice immunological assays; the biotech company Bionanoplus (Pamplona, Spain), who formulated the vaccine active principles to test intranasal versus intramuscular delivery; and the Faculty of Veterinary Sciences of the University of Córdoba, who managed the experimental work on pigs.

BIOMAP (2015-2017) was a project executed by a consortium led by the Spanish pharmaceutical manufacturers Laboratorios Rovi. The goal was to design assays to obtain bioactive molecules with the pharmaceutical criteria for quality, security and efficacy by following Quality by Design principles. Within the project, Vaxdyn prepared new active principles aimed for immunotherapy against infections produced by antibiotic-resistant Acinetobacter baumannii. The company obtained a battery of monoclonal antibodies and tested them for passive immunization of murine models. Other partners included the Andalusian biotechnology companies Bionaturis Group and Vivacell.

The project was funded by the competitive FEDER-INTERCONNECTA 2015 program of the Center for Industrial and Technological Development (CDTI) of the government of Spain, with the support of funds of the ERDF Programme of the European Union.

ADELIS (2013-2014) was a project executed by a consortium led by the Spanish pharmaceutical manufacturers Laboratorios Rovi. The goal was to to develop injectable pharmaceuticals for addressing medical needs from different health sectors. Within the project, Vaxdyn compared different technological platforms to deliver a vaccine against multi-drug resistant Acinetobacter baumannii and began to explore how the immunity raised by its first vaccine candidate against A. baumannii could lead to development of injectable sera to treat infections already established in the host. Other partners included the Andalusian biotechnology companies Bionaturis Group, Biomedal, and Althea.

The project was funded by the competitive FEDER-INTERCONNECTA 2013 program of the Center for Industrial and Technological Development (CDTI) of the government of Spain, with the support of funds of the ERDF Programme of the European Union.

ACINETOVAX (2011-2014) was a project funded by the competitive program INNPACTO 2011 of the Spanish Ministry of Science and Innovation, co-financed with the ERDF Programme of the European Union.

This project led to Vaxdyn being established as a spin-off from the Institute of Biomedicine of Seville (IBiS) for development of vaccine candidates against antibiotic-resistant infections. The project allowed completion the technology transfer process of technologies matured at the Infectious Diseases Group of the IBiS, led by Dr. Jerónimo Pachón and Dr. Michael McConnell, to Vaxdyn. Funding of this project allowed to achieve the first business milestone of Vaxdyn in its road to take to the final users preventive vaccines for ameliorating the global health crisis caused by superbacteria. The company acquired its technology that would be further developed until today.